Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03733210 · ClinicalTrials.gov registry record · Phase 1
Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer
A Phase 1 study, sponsored by Andrei Iagaru.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT03733210 is a Phase 1 study that has completed, run by Andrei Iagaru. The registered enrollment target is 14 participants.
The verdict
NCT03733210, a Phase 1 study, has completed, sponsored by Andrei Iagaru.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study evaluates how well panitumumab-IRDye800 and 89Zr-panitumumab work in identifying cancer that has spread to the lymph nodes in patients with squamous cell head and neck cancer. Panitumumab-IRDye800 is a drug that contains a dye molecule that fluoresces during surgery to indicate cancerous tissue. 89Zr-panitumumab is a drug that contains a small amount of radiation, which makes it visible in positron emission tomography (PET) scans. PET scans make detailed, computerized pictures of areas inside the body where the drug is used. Giving panitumumab-IRDye800 and 89Zr-panitumumab to patients with head and neck cancer may help doctors find metastatic lymph nodes better than current methods \[positron emission tomography (PET); computed tomography (CT); magnetic imaging resonance (MRI), or combinations\].
Interventions
- DRUG Panitumumab-IRDye800
- DEVICE Explorer Air camera
- DRUG 89-Zirconium (Zr-89) Panitumumab
- DEVICE Pinpoint IR IR9000 fluorescence imaging system (FIS)
- DEVICE SPY-PHI IR9000 fluorescence imaging system (FIS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2019-01-07 |
| Est. Completion | 2021-08-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03733210
The ClinicalTrials.gov registry entry for NCT03733210 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Andrei Iagaru, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Panitumumab-IRDye800 is the first listed.
NCT03733210 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03733210 about?
NCT03733210 is a clinical study titled "Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer". This study evaluates how well panitumumab-IRDye800 and 89Zr-panitumumab work in identifying cancer that has spread to the lymph nodes in patients with squamous cell head and neck cancer. Panitumumab-IRDye800 is a drug that contains a dye molecule that fluoresces during surgery to indicate cancerous ...
What is the current status of trial NCT03733210?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2019-01-07. Estimated completion is 2021-08-09.
What interventions are being tested in trial NCT03733210?
The interventions under investigation include: Panitumumab-IRDye800 (DRUG), Explorer Air camera (DEVICE), 89-Zirconium (Zr-89) Panitumumab (DRUG), Pinpoint IR IR9000 fluorescence imaging system (FIS) (DEVICE), SPY-PHI IR9000 fluorescence imaging system (FIS) (DEVICE).
Who is sponsoring clinical trial NCT03733210?
This trial is sponsored by Andrei Iagaru, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.